Will Anduril's valuation hit __ by December 31?
The conditions, incentives and evidence that could shape the answer.Will Anduril's valuation hit what level by December 31: the question behind the price
This is a specified private-market data-series test, not a general contest between financing headlines. A company can announce an impressive transaction without that consideration being the value the contract accepts. In the snapshot checked October 4, 2026 at 09:57 UTC, the focus outcome, ↑$150B, was quoted at 30.5%. [1]
NPM combines multiple pricing signals. [3] Our interpretation is that the decisive comparison pairs a threshold with a dated observation from the named provider. A company announcement can inform expectations without replacing that series. If public trading begins, the contract’s permitted market-price method changes the evidence to inspect.
The provider’s series is the operative measurement
Uses Nasdaq Private Market’s NPM Price-derived valuation through December 31, 2026, plus permitted IPO/direct-listing and regular-hours public-market values afterward. Acquisition consideration is excluded. Missing year-end data can wait until January 4, 2027; ordinary retrospective revisions are ignored, except clear-error corrections. [2]
The practical implication for ↑$150B is to distinguish necessary conditions from supporting clues. A plausible explanation can help identify what to investigate, but the outcome still turns on evidence satisfying the specified test. Read the named valuation series and its timing rules before translating a financing headline into a contract result.
What the other prices and the trading record reveal
Another open condition, ↑$175B, is priced at 23%, a 7.50-percentage-point difference from ↑$150B. Thresholds can be nested: satisfying a harder threshold can also satisfy an easier one. Their prices must therefore be interpreted as separate conditions, not vote shares that automatically sum to 100%. [1]
This event recorded $101,315 in cumulative turnover across its life. The captured record contains 7 eligible open constituent contracts. Those are the scope of this snapshot, not a count of independent forecasters. [1]
The next evidence that would change the assessment
For this event, watch NPM’s original daily observations and their publication times; any qualifying transition to public exchange pricing; the treatment of acquisitions, missing data and corrections. [2]
The next meaningful update is evidence about the required milestone or measurement. A changed quote by itself does not identify what happened or why. A qualifying original NPM valuation observation, or the permitted public-market value after listing, at the required threshold would support the outcome. A funding headline, acquisition consideration or nonqualifying revision can leave the threshold unproven even when it cites a larger number.
WEIGH BOTH SIDES
What would change the outlook?
Will Anduril's valuation hit (HIGH) $150B by December 31?
Quoted market evidence: Oct 4, 2026, 09:57 UTC. The live market panel may show a newer observation.
A qualifying original NPM valuation observation, or the permitted public-market value after listing, at the required threshold would support the outcome. [2]
A funding headline, acquisition consideration or nonqualifying revision can leave the threshold unproven even when it cites a larger number. [2]
The next signals to watch
The observed 30.5% quote is the captured market expectation for ↑$150B. Publicly known conditions alone do not establish that this price is too high or too low. [1]
Read the named valuation series and its timing rules before translating a financing headline into a contract result.
A FEW GOOD QUESTIONS
What else should you know?
Will Anduril's valuation hit what level by December 31?
The selected condition, ↑$150B, was priced at 30.5% when checked October 4, 2026 at 09:57 UTC. This is a specified private-market data-series test, not a general contest between financing headlines. A company can announce an impressive transaction without that consideration being the value the contract accepts. [1]
What evidence would be decisive for this particular outcome?
The key observations are NPM’s original daily observations and their publication times; any qualifying transition to public exchange pricing; the treatment of acquisitions, missing data and corrections. The full linked contract governs exceptions. [2]
Does this market price prove the event will happen?
No. 30.5% describes the quoted focus condition in a dated snapshot. It is not a verified forecast, an official result or evidence that all participants independently evaluated the same information. [1]
CHECK THE EVIDENCE
Sources & further reading
- Polymarket: Will Anduril's valuation hit __ by December 31? — observed event and constituent prices ↗polymarket.com
- Polymarket: Will Anduril's valuation hit (HIGH) $150B by December 31? — exact resolution rules ↗polymarket.com
- Nasdaq Private Market: Data and Intelligence ↗nasdaqprivatemarket.com
Published . AI-assisted, source-linked analysis. We distinguish evidence from interpretation; this article does not establish a trading edge. How we work →
